A study of redox properties of hydralazine hydrochloride, an antihypertensive drug

被引：14

作者：

Imad, Saima ^{[1
]}

Nisar, Shazia ^{[2
]}

Maqsood, Zahida T. ^{[2
]}

机构：

[1] Pakistan Council Sci & Ind Res, Natl Phys & Stand Lab, Chem Metrol Div, Islamabad, Pakistan

[2] Univ Karachi, Dept Chem, Karachi 32, Pakistan

来源：

JOURNAL OF SAUDI CHEMICAL SOCIETY | 2010年 / 14卷 / 03期

关键词：

Hydralazine hydrochloride; Gibbs free energy; Redox potential; Spectrophotometric analysis;

D O I：

10.1016/j.jscs.2010.02.003

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Hydralazine hydrochloride itself is a reducing agent and its redox properties like other reducing agents vary as the oxidizing agent and applied conditions vary. The redox properties of hydralazine were studied by spectrophotometric method. Formal redox potential of hydralazine was calculated and effect of pH was observed on redox properties of hydralazine. (C) 2010 King Saud University. All rights reserved.

引用

页码：241 / 245

页数：5

共 14 条

[1]

Carmody Melinda S, 2007, Cardiol Rev, V15, P46, DOI 10.1097/01.crd.0000250840.15645.fb

[2]

CHAMPE PC, 2000, LIPPINCOTTS ILLUSTRA, P190

[3]

CHRISTIAN GD, 2004, ANAL CHEM, P191

[4]

CLARKS, 1986, ANAL TOXICOLOGICAL D, P662

[5]

COX PA, 1995, ELEMENTS EARTH INORG, P166

[6] Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure [J].

Daiber, A ;

Oelze, M ;

Coldewey, M ;

Kaiser, K ;

Huth, C ;

Schildknecht, S ;

Bachschmid, M ;

Nazirisadeh, Y ;

Ullrich, V ;

Mülsch, A ;

Münzel, T ;

Tsilimingas, N .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 338 (04) :1865-1874

[7]

Dean John., 1973, LANGES HDB CHEM, V11th

[8]

HOUSECROFT CE, 2006, INTRO ORGANIC INORGA, P575

[9]

KATHERINE MH, 2004, MED TOXICOL, P714

[10] Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages [J].

Leiro, JM ;

Alvarez, E ;

Arranz, JA ;

Cano, E ;

Orallo, F .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (02) :163-177

← 1 2 →